$14.86
5.54% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Inhibrx Inc Stock price

$14.86
-0.51 3.32% 1M
-15.31 50.75% 6M
-18.72 55.75% YTD
-3.11 17.29% 1Y
-21.91 59.59% 3Y
-3.37 18.49% 5Y
-3.37 18.49% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.78 5.54%
ISIN
US45720L1070
Symbol
INBX
Sector
Industry

Key metrics

Market capitalization $215.11m
Enterprise Value $-9.58m
P/B ratio (TTM) P/B ratio 1.21
Cash position $196.33m
P/E forward 0.14
P/S forward 2,151.10
EV/Sales forward negative
Short interest 5.71%

Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Inhibrx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Inhibrx Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Inhibrx Inc forecast:

Hold
100%

Financial data from Inhibrx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.76 0.76
153% 153%
-
-0.76 -0.76
300% 300%
-
- Selling and Administrative Expenses 7.04 7.04
7% 7%
-
- Research and Development Expense 38 38
1% 1%
-
-46 -46
1% 1%
-
- Depreciation and Amortization 0.76 0.76
153% 153%
-
EBIT (Operating Income) EBIT -47 -47
2% 2%
-
Net Profit -44 -44
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibrx Inc Stock News

Neutral
PRNewsWire
12 days ago
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Positive
Seeking Alpha
21 days ago
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion,...
Neutral
PRNewsWire
22 days ago
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The j...
More Inhibrx Inc News

Company Profile

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Head office United States
CEO Mark Lappe
Founded 2010
Website www.inhibrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today